Use and spending on antineoplastic therapy for medicare beneficiaries with cancer

Medical Care

Volumn 51, Issue 4, 2013, Pages 351-360

  Davidoff, Amy J ^a,b,c   Shaffer, Thomas ^a,c   Erten, Mujde ^a,c   Shoemaker, J ^a   Zuckerman, Ilene ^a,c   Pandya, Naimish ^b   Stuart, Bruce ^a,c   Bryant Comstock, Lynda ^d   Shenolikar, Rahul ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Peter Lamy Center on Drug Therapy and Aging   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

antineoplastic therapy; cancer; Medicare; supplemental insurance

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; DRUG COST; FEMALE; HEALTH INSURANCE; HEALTH STATUS; HUMAN; MALE; MEDICARE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FINANCING, PERSONAL; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MEDICARE; MEDICARE PART D; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84884211816     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3182726ceb     Document Type: Article

References (22)

1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-128
2. Karaca-mandic P, McCullough JS, Siddiqui ma, et al. Impact of new drugs and biologics on colorectal cancer treatment and costs. Am J manag Care. 2011;17:e160-e168
3. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100: 888-897
4. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7:5-9
5. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618
6. Greco FA. Evolving role of oral chemotherapy for the treatment of patients with neoplasms. Oncology (Williston Park). 1998;12:43-50
7. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(suppl 3):S1-S14
8. Bagley GP, McVearry K. Medicare coverage for oncology services. Cancer. 1998;82:1991-1994
9. ACS cancer facts and figures supplemental data 2008. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/ 2008cafffinalsecuredpdf.pdf. Accessed September 27, 2012
10. Kaa K. Medicare challenges and solutions-reimbursement issues in treating the patient with colorectal cancer. J manag Care Pharm. 2007;13:S19-S26
11. Barnes L, Burich M, Little A, et al. "Oral Oncolytics/Addressing the Barriers to Access and Identifying Areas for Engagement," Avalere. Available at: http://www.avalerehealth.net/wm/show.php?c = &id = 842. Accessed February 9, 2012
12. Kaiser Family Foundation. Medicare Chartbook, 4th ed. 2010. Available at: http://facts.kff.org/chartbooks/Medicare%20Chartbook,%20Fourth %20edition,%202010.pdf
13. Weiner MG, Livshits A, Carozzoni C, et al. Derivation of malignancystatus from ICD-9 codes. AMIA Annu Symp Proc. 2003;2003: 1050
14. Travis K. Anastrozole data show continued delay in relapse, but no clear survival advantage. J Natl Cancer Inst. 2005;97:86-87
15. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319
16. Gold M.A.N., Jena AB, Lakdawalla DN, et al. The value of specialty oncology drugs. Health Serv Res. 2010;45:115-132
17. Gold M.A.N., Joyce GF, Lawless G, et al. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25:1319-1331
18. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEERMedicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(4):3-18
19. Cooper GS, Yuan Z, Stange KC, et al. The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care. 1999;37:436-444
20. Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9: 222-231
21. Koroukian SM, Bakaki PM, Beaird H, et al. Cancer stage comparison between dual Medicare-Medicaid eligibles using Medicaid as a supplemental health insurance program and low-income nonduals. J Public Health manag Pract. 2011;17:479-491
22. Poisal JA. Reporting of drug expenditures in the MCBS. Health Care Financ Rev. 2003;25:23-36